Clinical Trials

Ge announced that United BioPharma Inc. (UBP) has selected GE Healthcare’s FlexFactory manufacturing platform for its new facility in Hsinchu Industrial Park, Taiwan focusing on…
Read More...

The Feinstein Institute for Medical Research, and TheraSource LLC, a Long Island-based biotech company, announce today that they have received a Phase I Small Business Technology…
Read More...

NGM Bio’s NGM282 has met the primary and key secondary endpoints in a Phase 2 trial in nonalcoholic steatohepatitis (NASH) patients. NGM282, which is a non-tumorigenic, engineered…
Read More...

Tiziana Life Sciences plc, a clinical stage biotechnology company developing targeted drugs for cancer and autoimmune diseases, today announces the approval in Israel of a phase II…
Read More...

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for…
Read More...

Novartis announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to CTL019, an investigational chimeric antigen receptor T cell (CAR-T)…
Read More...

Agenus Inc. announced that the first patient has been dosed in a Phase 1/2 clinical trial of its anti-PD-1 antibody, AGEN2034. The open-label, dose-escalation portion of the trial is…
Read More...

uniQure N.V. announced that it will not pursue the renewal of the Glybera (alipogene tiparvovec) marketing authorization in Europe when it is scheduled to expire on October 25, 2017.…
Read More...

ReForm Biologics, a pharmaceutical technology company that develops proprietary excipients to improve biologic formulations, announced that the Company’s Board of Directors has…
Read More...

A certified CDISC provider and leader in pharmacometrics, Certara has developed a new solution which will enable sponsors to achieve new compliance requirements effortlessly
Read More...

Veeva Systems announced Veeva Vault SiteExchange, a cloud application that allows life sciences companies, CROs, and sites to easily access and exchange information during clinical…
Read More...

Regen BioPharma has identified three new series of compounds that activate NR2F6. These compounds are small molecules and were identified using Regen's patented screening methodology…
Read More...

Mateon announced that from its first schedule analysis from ongoing phase 2/3 Study(FOCUS) in patients with Platinum-resistant Ovarian Cancer result Positive. The analysis was…
Read More...

Prometic Life Sciences announced that it has received approval from FDA on the design of the first of its PBI-4050 planned phase 2/3 clinical trials for IPF based on the efficacy data…
Read More...

RXi Pharmaceuticals announced that Gerrit Dispersyn, Dr. Med Sc. has been appointed as RXi's Chief Development Officer effective April 24, 2017. RXi's current Chief Development…
Read More...

Allergan announced that it has entered into a clinical trial agreement with Novartis to conduct a Phase 2b study, using Allergan's cenicriviroc (CVC) and Novartis' lead FXR agonist for…
Read More...

Immune Therapeutics a clinical-stage biopharmaceutical company developing therapies for a range of conditions using Lodonal, its proprietary formulation of lower-dose naltrexone,…
Read More...

Biocryst announced that it has received approvals from Europe's initial regulatory to explore a new Oral liquid formulation of BCX7353 for the treatment of Acute attacks in patients…
Read More...

Novartis announced that it has it has it has exercised an option to in-license ECF843 for ophthalmic indication worldwide to strengthen R&D pipeline. The closing of the deal is…
Read More...

GE Healthcare and CBMG (Cellular Biomedicine Group) collaborated to co-develop certain industrial control processes in CAR-T (Chimeric Antigen Receptor T-cell) and stem-cell…
Read More...